Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. 1991

J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Selected acid-stable (2'-fluoro-2',3'-dideoxyarabinofuranosyl)adenine nucleosides containing methyl groups and other lipophilic functions at various positions in the adenine ring were prepared and evaluated as anti-HIV agents. The N6-methyl (1f), N6-benzoyl (1g), and 6-chloro (1i) analogues had modest activity, giving 30-50% protection to ATH8 cells infected with HIV. 2-Methyl (1d), 8-methyl (1h), and 2,N6-dimethyl (1e) substitution, as well as N1-oxide (21) formation, abolished the activity of the parent compound (1a). Several of these compounds, originally designed as agents for treating HIV in the central nervous system, were further investigated as substrates for adenosine deaminase (ADA). Kinetic experiments showed that ADA catalyzed the formation of the anti-HIV active inosine compound 1b from the N6-methyl analogue 1f in a quantitative manner. The anti-HIV activity of 1f and 1i was abolished when the ADA inhibitor, 2'-deoxycoformycin, was added to the test mixture. In contrast, the activity of 1f was significantly enhanced when ADA was added to the test system. These data indicate that 1f and 1i are prodrug forms of 1b in systems containing ADA.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides

Related Publications

J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
April 1996, Journal of medicinal chemistry,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
March 1995, Journal of medicinal chemistry,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
October 1992, Antimicrobial agents and chemotherapy,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
September 2006, Polskie Archiwum Medycyny Wewnetrznej,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
December 2023, Advanced science (Weinheim, Baden-Wurttemberg, Germany),
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
September 1987, Clinical chemistry,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
May 1987, Journal of medicinal chemistry,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
January 2002, Lupus,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
February 1991, Journal of medicinal chemistry,
J J Barchi, and V E Marquez, and J S Driscoll, and H Ford, and H Mitsuya, and T Shirasaka, and S Aoki, and J A Kelley
October 2015, Nature communications,
Copied contents to your clipboard!